Consistent with this, SARS-CoV-2 convalescent patients exhibit stronger S- and RBD-specific IgA responses in bronchoalveolar lavage (BAL) and saliva than infection-naïve vaccinees (Fig. 1) [110–112]. The gene discussed is CD79A; the disease is infection.